1 From Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at John Hopkins; City of Hope Comprehensive Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Moffitt Cancer Center; Fred & Pamela Buffett Cancer Center; The University of Texas MD Anderson Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Roswell Park Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Mayo Clinic Cancer Center; University of Michigan Comprehensive Cancer Center; University of Wisconsin Carbone Cancer Center; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; UC San Diego Moores Cancer Center; University of Colorado Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN Guidelines Panel meets at least annually to review comments from reviewers within the NCCN Member Institutions, examine relevant data, and reevaluate and update the recommendations. These NCCN Guidelines Insights summarize recent updates centered on treatment considerations for relapsed/refractory classic HL.
Provided content development and/or authorship assistance.